| abstract |
The invention falls within the field of autoimmune disease treatment and molecular immunology, and relates to an anti-IL-17A antibody, a pharmaceutical composition thereof and the use thereof. In particular, the invention relates to a monoclonal antibody or an antigen-binding fragment thereof, wherein the heavy chain variable region of the monoclonal antibody comprises: HCDR1-HCDR3 having amino acid sequences as shown in SEQ ID NOs: 31-33 respectively or HCDR1-HCDR3 having amino acid sequences as shown in SEQ ID NOs: 37-39 respectively, and the light chain variable region of the monoclonal antibody comprises: LCDR1-LCDR3 having amino acid sequences as shown in SEQ ID NOs: 34-36 respectively or LCDR1-LCDR3 having amino acid sequences as shown in SEQ ID NOs: 40-42 respectively. The monoclonal antibody of the present invention can specifically bind to IL-17A, specifically antagonizes the binding of IL-17A to the ligand thereof, and inhibit the activation of fibroblasts by IL-17A. |